Ultragenyx Q1 revenue $136M, net loss $1.84/share; reaffirms 2026 guidance; GTX-102 Phase 3 data H2 2026

Ultragenyx Pharmaceutical Inc.

2026-Q1 EPS reported -$1.84 revenue$136,000,000

Total revenue $136M (Q1 2025: $139M); Crysvita $93M, Dojolvi $18M, Evkeeza $18M, Mepsevii $7M.
Net loss $185M ($1.84/share) vs $151M ($1.57/share); operating expenses $305M including $30M restructuring.
Reaffirms 2026 total revenue guidance $730M-$760M; combined R&D and SG&A expenses flat to slightly down vs 2025.
DTX401 BLA for GSDIa granted Priority Review; PDUFA Aug 23, 2026. UX111 BLA resubmitted for MPS IIIA; PDUFA Sept 19, 2026.
GTX-102 Angelman Phase 3 data expected H2 2026; DTX301 Phase 3 showed significant ammonia reduction.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ultragenyx Pharmaceutical Inc. reported the quarter ended March 31, 2026 results: revenue $136 million. Guidance reaffirmed.

Period: the quarter ended March 31, 2026
Revenue: $136 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Higa ir@ultragenyx.com Media Jess Rowlands media@ultragenyx.com Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D

View on SEC.gov

Browse all earnings releases →

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-206368

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.